Mainz Biomed MYNZ Announces 50M in New Funding

Mainz Biomed NV (NASDAQ: MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today that it has entered into a $50 million Pre-Paid Advance Agreement (PPA) with Yorkville Advisors Global, LP (Yorkville), a global investment management firm. Simultaneously, the Company…Read More